Neuca

Neuca EPS

The Earnings per Share (EPS) of Neuca (NEU.WA) as of Oct 21, 2026 is 33.14 PLN. In the previous year, Earnings per Share (EPS) was 34.06 PLN — a change of -2.70% (lower).

EPS

33.14PLN

YoY

-2.70%

Last updated:

Earnings per Share (EPS) of Neuca is 2025 33.14 PLN. Earnings per Share (EPS) of Neuca was 2024 34.06 PLN. It decreases by -2.70% lower compared to the previous year.

The Neuca EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2024
34.06 PLN
Jan 1, 2025
33.14 PLN
Jan 1, 2026 (e)
46.45 PLN
Jan 1, 2027 (e)
56.22 PLN
Jan 1, 2028 (e)
61.73 PLN
Jan 1, 2029 (e)
80.37 PLN
Jan 1, 2030 (e)
64.75 PLN
Jan 1, 2031 (e)
70.50 PLN
The Neuca EPS history
YEAREPSYoY
est70.50PLN+8.88%
est64.75PLN-19.43%
est80.37PLN+30.18%
est61.73PLN+9.81%
est56.22PLN+21.02%
est46.45PLN+40.19%
33.14PLN-2.70%
34.06PLN+5.45%
32.30PLN+5.41%
30.64PLN-5.77%
32.51PLN+0.12%
32.47PLN+16.78%
27.81PLN+26.55%
21.97PLN+8.51%
20.25PLN-20.13%
25.36PLN+10.98%
22.85PLN+10.49%
20.68PLN+9.33%
18.91PLN+27.34%
14.85PLN+23.85%
11.99PLN+40.98%
8.51PLN+9.21%
7.79PLN+157.63%
3.02PLN-13.74%
3.50PLN+45.01%
2.42PLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuca Stock analysis

What does Neuca do? NEUCA SA generates revenue through the wholesale distribution of pharmaceutical products to pharmacies, leveraging its extensive network in the health market. The company also produces and sells its own branded drugs, supplements, and cosmetics, while offering clinical trials, telemedicine services, and IT solutions tailored for healthcare providers. Its e-commerce platform further supports the healthcare industry by enabling digital transactions for medical products and services. The primary buyers include pharmacies, healthcare institutions, and consumers seeking health-related products through online channels. NEUCA SA's business model integrates multiple revenue streams within the health sector, with a focus on both physical and digital distribution. The firm's own-brand products, such as pharmaceuticals and cosmetics, are sold directly to end-users and retail partners, while its IT solutions and telemedicine services target healthcare organizations. Clinical trials represent another key segment, attracting partnerships with research institutions and pharmaceutical firms. The company's operational scope spans from production to distribution, ensuring a comprehensive approach to healthcare market needs. The company's revenue is driven by its diversified portfolio, including drug distribution, branded product sales, and specialized services like telemedicine and clinical trials. Pharmacies remain the core customer segment for its wholesale operations, while e-commerce and IT solutions cater to a broader audience of healthcare providers and consumers. NEUCA SA's strategic positioning in the health market allows it to capitalize on multiple growth areas without relying on a single revenue source. Neuca is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuca stock

Earnings per Share (EPS) of Neuca is 33.14 PLN in 2025.

Earnings per Share (EPS) of Neuca changed from 34.06 PLN to 33.14 PLN, representing a -2.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Neuca since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Neuca

All Key Metrics — Neuca